Latest Breaking News On - Shan fu - Page 4 : comparemela.com

Vivo Capital and an Investor Syndicate Completes Sale of Surgical Specialties Corporation to GTCR-ba

Search jobs 01-Feb-2021 Vivo Capital and an Investor Syndicate Completes Sale of Surgical Specialties Corporation to GTCR-backed Corza Health PALO ALTO, Calif. (BUSINESS WIRE) Vivo Capital, a global healthcare investment firm, announced today that it has closed the sale of Surgical Specialties Corporation (“SSC”) to Corza Health, a portfolio company of GTCR, a global private equity firm. Vivo Capital and an investor syndicate including certain Vivo limited partner co-investors acquired SSC, a global manufacturer and leader in the medical device consumables segment, in 2017. Since then, SSC has acquired three companies, divested one product line to Angiodynamics, and built two factories in the US and China while reinvigorating the company’s iconic brands, including Quill™ and Sharpoint™.

乡村振兴的五种"味道"-半月谈

VISEN Pharmaceuticals Closes $150 Million Series B Financing to Accelerate the Development and Commercialization of its Innovative Endocrinology Therapies in Greater China

VISEN Pharmaceuticals Closes $150 Million Series B Financing to Accelerate the Development and Commercialization of its Innovative Endocrinology Therapies in Greater China News provided by Share this article SHANGHAI, Jan. 9, 2021 /PRNewswire/ VISEN Pharmaceuticals, a biotech company focused on developing and commercializing innovative endocrine drugs that address significant unmet needs for patients in Greater China, announced today the closing of a $150 million Series B financing. The round was led by Sequoia China with participation from OrbiMed, Sherpa Healthcare Partners, Cormorant, HBM Healthcare Investments, Pivotal bioVenture Partners China, Logos Capital, and CDG Capital, as well as all of the existing investors, including Ascendis Pharma A/S, Vivo Capital and Sofinnova Investments. Proceeds of the Series B financing will be used to accelerate the clinical development of the potential best-in-class portfolio drug candidates and to build a strong foundation for commer

Provivi® raises $45.5M to expand global launch

Provivi Team Successfully introducing insect pheromones to control damaging pests, the increased funding will strengthen the capacity for a global roll-out SANTA MONICA, CA, UNITED STATES, December 22, 2020 /EINPresswire.com/ Provivi, Inc. ( Provivi ), an emerging crop protection company using pheromones to protect large acreage row crops from major damaging insects, is pleased to inform the completion of a $45.5M financing round. Vivo Capital, a Palo Alto based investment fund, led the round. Returning shareholders, including Kairos Ventures, Temasek, Pontifax AgTech, Tybourne Capital, Lanx Capital, and Spruce Capital, also participated in the financing. The Series C-2 financing is a new milestone in the growth of our company. It builds upon a very successful year where Provivi achieved several product registrations worldwide and launched our first product commercially in Mexico, said Dr. Pedro Coelho, Co-Founder and CEO of Provivi.